Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?

ConclusionsDespite the definition of a life expectancy of  >  3 months as a standard inclusion criterion in clinical trials for advanced PC, a significant proportion of study patients does not survive >  3 months.Trial registration numbersNCT00440167 (AIO-PK0104), NCT01729481 (RASH), NCT01728818 (ACCEPT).
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research